Please wait a minute...
European Journal of Gynaecological Oncology  2020, Vol. 41 Issue (4): 517-522    DOI: 10.31083/j.ejgo.2020.04.5335
Original Research Previous articles | Next articles
The prognostic significance and immuno-expression of survivin, mutant p53 and bcl-2 in 92 cases of epithelial ovarian cancer
Chados Nikolaos1, *(), Gregoriou Odysseas2, Salakos Nicolaos2, Kondis Agatha3, Deligeoroglou Efthymios4
1Chelsea and Westminster University Hospital, NHS Foundation Trust, London, United Kingdom
2Second Department of Obstetrics and Gynaecology, National and Kapodistrian University of Athens Medical School, Aretaieio Hospital, Athens, Greece
3Department of Pathology, National and Kapodistrian University of Athens Medical School, Aretaieio Hospital, Athens, Greece
4Second Department of Obstetrics and Gynaecology, Paediatric and Adolescent Gynaecology, National and Kapodistrian University of Athens Medical School, Aretaieio Hospital, Athens, Greece
Download:  PDF(995KB)  ( 206 ) Full text   ( 9 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Background: Survivin is a member of the inhibitors of apoptosis protein family, commonly detected in human cancers and fetal tissue, with the ability to regulate programmed cell death and cell division. Aim of this study is to investigate the immuno-expression of survivin and its correlation with other anti-apoptotic markers (mutant p53 and bcl-2) in human ovarian cancer and assess the prognostic significance and possible therapeutic role of this protein in the future. Materials and Methods: Ninety-two cases of primary epithelial ovarian cancer over a 10-year period were included in the study. Sixty-six cases were diagnosed with serous ovarian cancer and twenty-six with endometrioid. All cases were fixed in formalin and paraffin-embedded standard techniques and processed by an immunostain method, in order to assess the survivin-positive cases and their prevalence in nucleus or cytoplasm. Results: Survivin cytoplasmic immuno-expression is associated with more advanced stage and grade of the ovarian disease. Nuclear survivin was more pronounced in tumors with better prognosis. Mutant p53 and bcl-2 were also positively co-expressed and associated with poor survival rate in all cases of serous ovarian carcinoma. Neither survivin nor bcl-2 were expressed in any case of endometrioid ovarian cancer. Conclusion: Survivin can play a key role as a potential future tumor marker to determine prognosis and predict response to various therapies.
Key words:  Survivin      p53      Bcl-2      Prognosis      Ovary      Cancer     
Submitted:  07 August 2019      Accepted:  30 October 2019      Published:  15 August 2020     
*Corresponding Author(s):  CHADOS NIKOLAOS     E-mail:  nchados@yahoo.com

Cite this article: 

Chados Nikolaos, Gregoriou Odysseas, Salakos Nicolaos, Kondis Agatha, Deligeoroglou Efthymios. The prognostic significance and immuno-expression of survivin, mutant p53 and bcl-2 in 92 cases of epithelial ovarian cancer. European Journal of Gynaecological Oncology, 2020, 41(4): 517-522.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2020.04.5335     OR     https://ejgo.imrpress.com/EN/Y2020/V41/I4/517

[1] Yi-fan Luo, Li-xiang Ren, Ming-yan Jiang, Yang Chu. A systematic review and meta-analysis on the effects of metformin on survival outcomes and risk in women with cervical cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 504-507.
[2] Liman Yang, Jing Jin, Juhong Liu. Correlation of MMP2-C1306T (rs243865) and MMP7-181A/G (rs11568818) with cervical cancer: a meta-analysis[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 508-512.
[3] Rie Nakamura, Yuko Shimoji, Tadaharu Nakasone, Yusuke Taira, Yoshihisa Arakaki, Tomoko Nakamoto, Keiko Mekaru, Wataru Kudaka, Tatsuya Kinjo, Yoichi Aoki. Malignant bowel obstruction in recurrent gynecologic cancers: who will benefit from palliative surgical intervention?[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 513-516.
[4] Silvia Ortega, José Angel Mínguez, José Manuel Aramendía, Marta Santisteban, Fernando Martinez-Regueira, Pablo Martí-Cruchaga, Juan Luis Alcázar, Matías Jurado. The impact of secondary cytoreductive surgery on survival in first recurrence of platinum sensitive epithelial ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 523-530.
[5] Yusuf Cakmak, Tufan Oge. The effect of age on prediction of concurrent endometrial cancer in patients with atypical endometrial hyperplasia[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 531-535.
[6] Sun Yi Choe, Jung-Woo Park. Prognostic significance of the number of metastatic lymph nodes in early cervical cancer: a retrospective study[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 536-540.
[7] Jae Hong Sang, Soo-Ho Chung. Is it enough in ovarian cancer staging surgery to laparoscopic surgery? Comparison of surgical methods[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 541-544.
[8] Panteleimon Mnimatidis, Abraham Pouliakis, George Valasoulis, George Michail, Aris Spathis, Christine Cottaridi, Niki Margari, Maria Kyrgiou, Maria Nasioutziki, Alexandros Daponte, Konstantinos Dinas, Evangelos Paraskevaidis, Ioannis Panayiotides, Dimitrios-Dionysios Koutsouris. Multicentric assessment of cervical HPV infection co-factors in a large cohort of Greek women[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 545-555.
[9] Ji Young Park, Gun Oh Chong, Yoon Hee Lee, Hyun Jung Lee, Chul Min Park, Eun Hye Lee, Dae Gy Hong. Transmembrane G protein–coupled receptor 30 (GPR30) gene polymorphisms in Korean Women with Ovarian Cancer: An experimental study[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 556-562.
[10] Hayal Uzelli Şimşek, Turgay Şimşek, Deniz Şahin, Sertaç Ata Güler, Nuh Zafer Cantürk, Nihat Zafer Utkan. Evaluation of the effect of surgical timing on systemic response to trauma in premenopausal patients by using cytokine levels[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 577-582.
[11] Zeyneb Bakacak, Mustafa Kaplanoğlu, Murat Bakacak, Tuncay çelik. Demodex folliculorum mite infestation in gynecological cancers: A case control study[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 583-586.
[12] Sigit Purbadi, Gregorius Tanamas, Lisa Novianti. Advanced stage ovarian cancer survival in Jakarta[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 587-590.
[13] Fengmei Wang , Huachun Luo , Huihua Cheng, Huijuan Huang , Zhichao Fu. Is 3D printing-gided three-dimensional brachytherapy suitable for cervical cancer: from one single research institute?[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 591-597.
[14] Di Wu, Jirui Zhang, Chengxi Yang. Effect of letrozole combined with testosterone on the proliferation and apoptosis of endometrial carcinoma cells[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 604-608.
[15] Gen-Hai Zhu, Kang Wang, Lan Hong, Xin-Hui Fu, Fu-Jin Liu, Hai-Yan Huang. Safety and efficacy of fertility-sparing surgery for an orthotopic xenograft model of epithelial ovarian cancer in nude mice[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 609-616.
No Suggested Reading articles found!